Core Viewpoint - Hillman Solutions Corp. (HLMN) has seen a 13.1% increase in share price over the past four weeks, closing at $7.77, with a potential upside of 40.8% based on Wall Street analysts' mean price target of $10.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.54, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting a 3% increase, while the highest estimate is $15.00, indicating a potential surge of 93.1% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][9] Analyst Optimism and Earnings Estimates - Analysts show strong agreement in revising HLMN's earnings estimates upward, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - HLMN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - The combination of a positive earnings outlook and a strong Zacks Rank suggests a more conclusive indication of the stock's potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of HLMN's potential gains, the direction indicated by these targets appears to be a useful guide for further research [14]

Core Viewpoint - Red Robin (RRGB) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $9.38 indicating a potential upside of 49.1% from the current price of $6.29 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.94, where the lowest estimate is $3.50 (44.4% decline) and the highest is $12.00 (90.8% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RRGB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 14.5%, with one estimate moving higher and no negative revisions [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Nurix Therapeutics, Inc. (NRIX) has seen a 2.3% increase in share price over the past four weeks, closing at $12.44, with analysts suggesting a potential upside of 143.4% based on a mean price target of $30.28 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49, indicating variability among estimates [2] - The lowest estimate suggests a 28.6% increase from the current price, while the highest estimate indicates a 229.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about NRIX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and no negative revisions [12] Zacks Rank - NRIX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Quanex Building Products (NX) closed at $18.93, with a 9.3% gain over the past four weeks, and a mean price target of $37 indicates a potential upside of 95.5% [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $31.00 suggests a 63.8% increase, and the highest estimate of $42.00 indicates a 121.9% surge [2] - Analysts show strong agreement on NX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for NX's current year earnings has increased by 1.8% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - FB Financial (FBK) shares have shown a 1.9% increase over the past four weeks, closing at $44.46, with a potential upside of 25.1% based on Wall Street analysts' price targets [1][11]. Price Targets - The average price target for FBK is $55.6, with estimates ranging from a low of $51.00 to a high of $59.00, indicating a standard deviation of $3.78 [2]. - The lowest estimate suggests a 14.7% increase, while the highest points to a 32.7% upside [2]. Analyst Consensus and Earnings Estimates - Analysts have shown strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 0.8% over the past month, with one estimate rising and no negative revisions [12]. Zacks Rank - FBK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13]. Price Target Reliability - While consensus price targets are often used by investors, they should be approached with skepticism due to historical inaccuracies in predicting actual stock price movements [3][10]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research [9].

Shares of Semtech (SMTC) have gained 2.2% over the past four weeks to close the last trading session at $40.23, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $56.33 indicates a potential upside of 40%.The average comprises 12 short-term price targets ranging from a low of $43.00 to a high of $68.00, with a standard deviation of $8.32. While the lowest estimate indicates an inc ...

Group 1 - Manchester United (MANU) closed at $17.01, with an 18% gain over the past four weeks, and a mean price target of $21.97 suggests a 29.2% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $4.64, indicating variability among analysts; the lowest estimate is $16.90 (0.7% decline), while the highest is $26 (52.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with a 48.7% increase in the Zacks Consensus Estimate for the current year, indicating potential upside for the stock [12][11] Group 2 - The Zacks Rank for MANU is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - While price targets are often viewed as a metric for investment decisions, they can mislead investors; analysts may set overly optimistic targets due to business incentives [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]

Core Viewpoint - EverQuote (EVER) shares have increased by 6.4% in the past four weeks, closing at $24.61, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $34.17, representing a 38.9% increase [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.79, where the lowest estimate of $30 indicates a 21.9% increase, and the highest estimate suggests a 54.4% surge to $38 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts show increasing optimism about EverQuote's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2.3% over the past month, with one estimate increasing and no negative revisions [12] - EverQuote holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Core Viewpoint - Verve Therapeutics (VERV) has shown a significant price increase of 25.4% over the past four weeks, with a mean price target of $24.75 indicating a potential upside of 367.9% from its current price of $5.29 [1] Price Targets and Analyst Consensus - The average price target for VERV includes estimates ranging from a low of $15 to a high of $39, with a standard deviation of $7.81, indicating variability among analysts [2] - The lowest estimate suggests an increase of 183.6%, while the most optimistic estimate points to a 637.2% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about VERV's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher [11] - Over the last 30 days, five estimates have moved higher with no negative revisions, leading to a 9.6% increase in the Zacks Consensus Estimate [12] - VERV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - HNI shares have increased by 8.8% over the past four weeks, closing at $47.26, with a mean price target of $69.50 indicating a potential upside of 47.1% [1] - The average price targets range from a low of $63 to a high of $80, with a standard deviation of $7.59, suggesting a consensus among analysts [2] - Analysts have shown increasing optimism regarding HNI's earnings prospects, with a 7.2% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - HNI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The positive trend in earnings estimate revisions is correlated with potential stock price movements, indicating a legitimate reason for expecting an upside [11] - Analysts' price targets, while often overly optimistic, can provide a starting point for further research into the stock's potential [9][10]